| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
HIV-1 protease
|
|---|---|
| ln Vitro |
R is separated from Rosamultin. At a 100 μM concentration, rugosa roots inhibit HIV-1 protease by 53% [1].
Rosamultin showed an inhibitory effect of 52.9 ± 2.0% against HIV-1 protease at a concentration of 100 μM in a cell-free enzymatic assay. Among seven compounds isolated from R. rugosa (gallic acid, methyl gallate, quercetin, hyperoside, (+)-catechin, rosamultin, and kaji-ichigoside F1), rosamultin exhibited the most potent inhibitory activity (53%) against HIV-1 protease at 100 μM. |
| Enzyme Assay |
The HIV-1 protease inhibitory activity was measured using a recombinant HIV-1 protease prepared in-house. The substrate used was His-Lys-Ala-Arg-Val-Leu-(pNO2-Phe)-Glu-Ala-Nle-Ser-NH2. The enzyme stock solution was diluted for the assay. Test compounds were dissolved in dimethyl sulfoxide (10% in the reaction mixture). The reaction mixture (5 μL total volume) consisted of 1 μL of 50 mM sodium acetate buffer (pH 5.0), 1 μL of substrate solution, 1 μL of the test compound solution (or plant extract), and 2 μL of HIV-1 protease solution. The mixture was stirred, centrifuged, and incubated at 37°C for 1 hour in a microtube. A control reaction was performed under identical conditions without the test compound. The reaction was terminated by heating at 90°C for 1 minute. Then, 35 μL of sterile water was added, and a 5 μL aliquot was analyzed by HPLC. The hydrolysate and remaining substrate were quantitatively analyzed by reversed-phase HPLC on a C18 column (150 × 4.6 mm i.d.) with a linear gradient of acetonitrile from 20% to 40% in 0.1% trifluoroacetic acid at a flow rate of 1.0 mL/min, with detection at 280 nm. The retention times of the substrate and the pNO2-Phe-bearing hydrolysate were approximately 9 and 4 minutes, respectively. Inhibitory activity was calculated as: % inhibition = (A_control - A_sample) × 100 / A_control, where A is the relative peak area of the hydrolysate. Rosamultin was tested at 100 μM and showed 52.9% inhibition. [2]
|
| References | |
| Additional Infomation |
Rosamultin has reportedly been found in Rosa laevigata, Rubus ellipticus var. obcordatus, and other organisms for which data is available.
Rosamultin is an ursane-type triterpenoid isolated from the root of Rosa rugosa. The root of R. rugosa has been used as an antidiabetic in Korean folkloric medicine and has been reported to have hypolipidemic effects and DPPH radical-scavenging activity. Among naturally occurring ursane-type triterpenoids, ursolic acid and uvaol were previously reported to have HIV protease inhibitory activity; the malonyl hemiester of ursolic acid showed more potent activity. In this study, rosamultin showed the most potent inhibition (53%) among the tested compounds from R. rugosa at 100 μM. [2] |
| Molecular Formula |
C36H58O10
|
|---|---|
| Molecular Weight |
650.8397
|
| Exact Mass |
650.403
|
| CAS # |
88515-58-6
|
| PubChem CID |
21122581
|
| Appearance |
White to off-white solid powder
|
| Density |
1.31g/cm3
|
| Boiling Point |
741.5ºC at 760 mmHg
|
| Flash Point |
223.6ºC
|
| Index of Refraction |
1.604
|
| LogP |
2.433
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
46
|
| Complexity |
1250
|
| Defined Atom Stereocenter Count |
16
|
| SMILES |
C([C@]12CC[C@@H](C)[C@](O)(C)[C@H]1C1=CC[C@@H]3[C@]4(C[C@@H](O)[C@H](O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@@]1(CC2)C)C)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
|
| InChi Key |
MLKQAGPAYHTNQQ-BRDPIYJESA-N
|
| InChi Code |
InChI=1S/C36H58O10/c1-18-10-13-36(30(43)46-29-26(41)25(40)24(39)21(17-37)45-29)15-14-33(5)19(27(36)35(18,7)44)8-9-23-32(4)16-20(38)28(42)31(2,3)22(32)11-12-34(23,33)6/h8,18,20-29,37-42,44H,9-17H2,1-7H3/t18-,20-,21-,22+,23-,24-,25+,26-,27-,28+,29+,32+,33-,34-,35-,36+/m1/s1
|
| Chemical Name |
[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1R,2R,4aS,6aR,6aS,6bR,8aR,10R,11R,12aR,14bS)-1,10,11-trihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~153.65 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.84 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.84 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.84 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5365 mL | 7.6824 mL | 15.3648 mL | |
| 5 mM | 0.3073 mL | 1.5365 mL | 3.0730 mL | |
| 10 mM | 0.1536 mL | 0.7682 mL | 1.5365 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
